Lenalidomide-mediated Erythroid Improvement in Non-del(5q) Myelodysplastic Syndromes is Associated with Bone Marrow Immuno-remodeling

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2017 Oct 4

PMID 28972593

Citations 3

Authors

G Kerdivel

V Chesnais

E Becht

A Toma

N Cagnard

F Dumont

A Rousseau

P Fenaux

S Chevret

N Chapuis

V Boeva

W H Fridman

M Fontenay

O Kosmider

Affiliations

Soon will be listed here.

Citing Articles

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.

van de Loosdrecht A, Cremers E, Alhan C, Duetz C, In t Hout F, Visser-Wisselaar H Leukemia. 2024; 38(4):840-850.

PMID: 38297135 PMC: 10997501. DOI: 10.1038/s41375-024-02161-6.

Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes.

Drusbosky L, Cogle C Int J Mol Sci. 2020; 21(9).

PMID: 32397113 PMC: 7246771. DOI: 10.3390/ijms21093323.

Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide.

Mahrle T, Akyuz N, Fuchs P, Bonzanni N, Simnica D, Germing U Haematologica. 2019; 104(7):1355-1364.

PMID: 30655375 PMC: 6601099. DOI: 10.3324/haematol.2018.208223.

References

Ebert B, Galili N, Tamayo P, Bosco J, Mak R, Pretz J . An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med. 2008; 5(2):e35. PMC: 2235894. DOI: 10.1371/journal.pmed.0050035. View

List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E . Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006; 355(14):1456-65. DOI: 10.1056/NEJMoa061292. View

Sternberg A, Killick S, Littlewood T, Hatton C, Peniket A, Seidl T . Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. Blood. 2005; 106(9):2982-91. DOI: 10.1182/blood-2005-04-1543. View

Santini V, Almeida A, Giagounidis A, Gropper S, Jonasova A, Vey N . Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. J Clin Oncol. 2016; 34(25):2988-96. DOI: 10.1200/JCO.2015.66.0118. View

Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C . Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia. 2015; 30(4):897-905. DOI: 10.1038/leu.2015.296. View

Becht E, Giraldo N, Lacroix L, Buttard B, Elarouci N, Petitprez F . Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016; 17(1):218. PMC: 5073889. DOI: 10.1186/s13059-016-1070-5. View

Kronke J, Fink E, Hollenbach P, MacBeth K, Hurst S, Udeshi N . Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature. 2015; 523(7559):183-188. PMC: 4853910. DOI: 10.1038/nature14610. View

Sloand E, Mainwaring L, Fuhrer M, Ramkissoon S, Risitano A, Keyvanafar K . Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood. 2005; 106(3):841-51. PMC: 1895154. DOI: 10.1182/blood-2004-05-2017. View

Aggarwal S, van de Loosdrecht A, Alhan C, Ossenkoppele G, Westers T, Bontkes H . Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy. Br J Haematol. 2011; 153(5):568-81. DOI: 10.1111/j.1365-2141.2011.08683.x. View

10.

Basiorka A, McGraw K, De Ceuninck L, Griner L, Zhang L, Clark J . Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41. Cancer Res. 2016; 76(12):3531-40. PMC: 4911265. DOI: 10.1158/0008-5472.CAN-15-1756. View

11.

Kiladjian J, Bourgeois E, Lobe I, Braun T, Visentin G, Bourhis J . Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia. 2006; 20(3):463-70. DOI: 10.1038/sj.leu.2404080. View

12.

Chesnais V, Renneville A, Toma A, Lambert J, Passet M, Dumont F . Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. Blood. 2015; 127(6):749-60. PMC: 4937206. DOI: 10.1182/blood-2015-04-640128. View

13.

Komrokji R, Lancet J, Swern A, Chen N, Paleveda J, Lush R . Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. Blood. 2012; 120(17):3419-24. DOI: 10.1182/blood-2012-03-415661. View

14.

Hsu A, Quach H, Tai T, Prince H, Harrison S, Trapani J . The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood. 2010; 117(5):1605-13. DOI: 10.1182/blood-2010-04-278432. View

15.

Linton P, Dorshkind K . Age-related changes in lymphocyte development and function. Nat Immunol. 2004; 5(2):133-9. DOI: 10.1038/ni1033. View

16.

Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M . A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011; 118(14):3765-76. DOI: 10.1182/blood-2011-01-330126. View

17.

McDaniel J, Zou J, Fulp W, Chen D, List A, Epling-Burnette P . Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation. Leukemia. 2011; 26(6):1425-9. PMC: 3321111. DOI: 10.1038/leu.2011.359. View